IL-10 is required for prevention of necrosis in the small intestine and mortality in both genetically resistant BALB/c and susceptible C57BL/6 mice following peroral infection with Toxoplasma gondii

被引:179
作者
Suzuki, Y
Sher, A
Yap, G
Park, D
Neyer, LE
Liesenfeld, O
Fort, M
Kang, H
Gufwoli, E
机构
[1] Palo Alto Med Res Fdn, Res Inst, Dept Immunol & Infect Dis, Palo Alto, CA 94301 USA
[2] Stanford Univ, Dept Med, Div Infect Dis & Geog Med, Sch Med, Stanford, CA 94305 USA
[3] NIAID, Immunobiol Sect, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA
[4] DNAX Res Inst Mol & Cellular Biol Inc, Dept Immunol, Palo Alto, CA 94304 USA
关键词
D O I
10.4049/jimmunol.164.10.5375
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The role for IL-10 in the immunopathogenesis of acute toxoplasmosis following peroral infection was examined in both genetically susceptible C57BL/6 and resistant BALB/c mice. C57BL/6-background IL-10-targeted mutant (IL-10(-/-)) mice all died in 2 wk after infection with 20 cysts of the ME49 strain, whereas only 20% of control mice succumbed. Histological studies revealed necrosis in the small and large intestines and livers of infected IL-10(-/-) mice, The necrosis in the small intestine was the most severe pathologic response and was not observed in control mice. Treatment of infected IL-10(-/-) mice with either anti-CD4 or anti-IFN-gamma mAb prevented intestinal pathology and significantly prolonged time to death. Treatment of these animals with anti-IL-12 mAb also prevented the pathology. Significantly greater amounts of IFN-gamma, mRNA were detected in the lamina propria lymphocytes obtained from the small intestine of infected IL-10(-/-) mice than those from infected control mice, In common with C57BL/6-background IL-10(-/-) mice, BALB/c-background IL-10(-/-) mice all died developing intestinal pathology after infection. Control BALB/c mice all survived even after infection with 100 cysts and did not develop the intestinal lesions. Treatment with anti-IFN-gamma mAb prevented the pathology and prolonged time to death of the infected n-10(-/-) mice, These results strongly suggest that IL-10 plays a critical role in down-regulating IFN-gamma production in the small intestine following sublethal peroral infection with Toxaplasma gondii and that this do,vn-regulatory effect of IL-10 is required for prevention of development of IFN-gamma-mediated intestinal pathology and mortality in both genetically resistant BALB/c and susceptible C57BL/6 mice.
引用
收藏
页码:5375 / 5382
页数:8
相关论文
共 37 条
[1]  
Berger EW, 1900, MEM BIOL LAB J HOPKI, V4, P1
[2]   INFLUENCE OF GENES WITHIN THE MHC ON MORTALITY AND BRAIN CYST DEVELOPMENT IN MICE INFECTED WITH TOXOPLASMA-GONDII - KINETICS OF IMMUNE REGULATION IN BALB H-2 CONGENIC MICE [J].
BLACKWELL, JM ;
ROBERTS, CW ;
ALEXANDER, J .
PARASITE IMMUNOLOGY, 1993, 15 (06) :317-324
[3]  
BuzoniGatel D, 1997, J IMMUNOL, V158, P5883
[4]   2 TYPES OF MOUSE HELPER T-CELL CLONE .3. FURTHER DIFFERENCES IN LYMPHOKINE SYNTHESIS BETWEEN TH1 AND TH2 CLONES REVEALED BY RNA HYBRIDIZATION, FUNCTIONALLY MONOSPECIFIC BIOASSAYS, AND MONOCLONAL-ANTIBODIES [J].
CHERWINSKI, HM ;
SCHUMACHER, JH ;
BROWN, KD ;
MOSMANN, TR .
JOURNAL OF EXPERIMENTAL MEDICINE, 1987, 166 (05) :1229-1244
[5]   TOXOPLASMA-GONDII INFECTION OF THE CENTRAL NERVOUS-SYSTEM - USE OF THE PEROXIDASE-ANTIPEROXIDASE METHOD TO DEMONSTRATE TOXOPLASMA IN FORMALIN FIXED, PARAFFIN EMBEDDED TISSUE-SECTIONS [J].
CONLEY, FK ;
JENKINS, KA ;
REMINGTON, JS .
HUMAN PATHOLOGY, 1981, 12 (08) :690-698
[6]   T helper cell 1-type CD4(+) T cells, but not B cells, mediate colitis in interleukin 10-deficient mice [J].
Davidson, NJ ;
Leach, MW ;
Fort, MM ;
ThompsonSnipes, L ;
Kuhn, R ;
Muller, W ;
Berg, DJ ;
Rennick, DM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (01) :241-251
[7]   PREPARATION AND PURIFICATION OF LYMPHOCYTES FROM THE EPITHELIUM AND LAMINA PROPRIA OF MURINE SMALL-INTESTINE [J].
DAVIES, MDJ ;
PARROTT, DMV .
GUT, 1981, 22 (06) :481-488
[8]  
DIALYNAS DP, 1983, J IMMUNOL, V131, P2445
[9]  
Fort MM, 1998, J IMMUNOL, V161, P3256
[10]  
GAZZINELLI RT, 1991, J IMMUNOL, V146, P286